|
| |
| Drug Development |
|
ReceptoPharm is developing proprietary
therapeutic protein products for the treatment of neurological,
viral and and autoimmune disorders. |
| »
Learn More |
|
|
| |
| CRO Services |
ReceptoPharm offers a full range of contract
research services catering to small and start-up biotech companies. |
| » Learn More |
|
|
|
ReceptoPharm's research and development
pipeline consists of several novel therapies
in various stages of development to prevent
and/or treat Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy
(AMN), Herpes, Rheumatoid Arthritis (RA)
and Pain.
| |
Planning |
|
| |
In Progress |
|
| |
Completed |
|
|
|
Abbreviations
Preclinical (PC), Phase 1 (P-I), Phase 2
(P-II), Phase 3 (P-III)
| |
Indication |
PC |
P-I |
P-II |
P-III |
| |
|
|
|
|
|
| |
|
|
|
|
|
|
| |
Indication |
Regulatory Status |
| |
Chronic Pain (Over-the-Counter) |
Marketing |
|
| |
 |
|
| Cobroxin is the first over-the-counter pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. For more information, visit http://www.Cobroxin.com. |
|
|
|
|
|
| |
| E-Alerts
|
| Signup to receive news and announcements
from ReceptoPharm and Nutra Pharma: |
|
|
|
|
|
|
|
